All In Biotech

Drug Trial Radar · NCT07160335

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetic Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® (US-sourced Keytruda®) in Multiple Resected Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 174 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

174

Planned (sponsor's estimate)

Start

Sep 26, 2025

Primary completion

Apr 30, 2027

Study completion Mar 27, 2028

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Sep 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs. US-sourced Keytruda® in patients with resected non-small cell lung cancer (NSCLC) or melanoma (MEL), or renal cell carcinoma (RCC).

Conditions

  • Non-small Cell Lung Cancer
  • Melanoma
  • Renal Cell Carcinoma

Interventions

  • HLX17Drug

    Subjects will receive HLX17 (200 mg) on Day 1 of each 3-week cycle

  • US-sourced Keytruda®Drug

    Subjects will receive US-sourced Keytruda® (200 mg) on Day 1 of each 3-week cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-21dTime frame: rom time 0 to 21 days after the 1st dose (3 weeks)
  2. AUCssTime frame: from time 0 to 21 days after the 6th dose (18 weeks)

Locations

69 sites in 4 countries. Site status is shown where the registry gives one.

  • Oncology Physicians Network (OPN) - Glendale

    Glendale, California

  • Oncology Physicians Network (OPN)- Los Alamitos

    Los Alamitos, California

  • HCA

    Los Angeles, California

  • Los Angeles Cancer Network

    Los Angeles, California

  • Oncology Physicians Network (OPN) - San Bernardino

    San Bernardino, California

  • BRCR Global

    Deerfield Beach, Florida

  • D&H National Research Center

    Margate, Florida

  • Ocala Oncology

    Ocala, Florida

  • Mid Florida Hematology and oncology Center

    Orange City, Florida

  • Oncology Consulatants (P1 Trials -Exigent Network)

    Houston, Texas

  • American Oncology Network Vista Oncology Division

    Olympia, Washington

  • Northwest Medical Specialties PPLC (P1 Trials - Exigent Network )

    Tacoma, Washington

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Beijing Chest Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Hunan Provincial Cancer Hospital

    Hunan, Changsha, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The Second Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of University of South China

    Hengyang, Hunan, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China

  • Guangxi Medical University Cancer Center

    Guangxi, Nanning, China

  • Binzhou Medical University Hospital

    Binzhou, Shandong, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.